钇 90治疗不可切除且化疗耐受结直肠癌肝转移的研究进展
Research progress of Yttrium 90 in the treatment of unresectable and chemotherapy tolerant colorectal liver metastasis
-
摘要:
结直肠癌肝转移是临床上常见的肝脏转移性肿瘤,预后差。不可切除且化疗耐受的结直肠癌肝转移患者成为临床上治疗的难点。钇 90治疗不可切除且化疗耐受的结直肠癌肝转移安全有效,其肿瘤控制率为63%~78%,中位生存时间为10.5个月,1、2、3年患者生存率分别为44%、20%、14%。对于部分患者钇 90治疗较分子靶向药物及其他局部微创治疗具有明显的优势。虽然钇 90治疗不可切除且化疗耐受的结直肠癌肝转移取得了一定的疗效,但仍需多中心随机对照研究进一步验证其有效性及安全性。
Abstract:Colorectal liver metastasis (CRLM) is a common liver metastatic tumor with poor prognosis. It was very difficult to treat patients with unresectable and chemotherapy tolerant CRLM. With the tumor control rate ranging from 63% to 78%, Yttrium-90 is both safe and effective in treating unresectable and chemotherapytolerant CRLM. The median survival time is 10.5 months, and the 1, 2, 3 year overall survival rates of patients are 44%, 20% and 14% respectively. For a certain portion of patients, Yttrium-90 has distinct advantages over molecular targeted drugs and other local minimally invasive treatment. Though Yttrium90 treatment has showed certain curative effect, its safety and effectiveness require further confirmation through multicenter randomized controlled trial.
-
Keywords:
- Colorectal neoplasms /
- Liver metastases /
- Yttrium-90 /
- Therapy
-
计量
- 文章访问数: 9015
- HTML全文浏览量: 0
- PDF下载量: 0